Systematic review of the economic value of diarrheal vaccines

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1582-1594

  Rheingans, Richard ^a   Amaya, Mirna ^a   Anderson, John D ^a   Chakraborty, Poulomy ^a   Atem, Jacob ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cost effectiveness; Diarrhea; Economic; Enteric; Vaccine; Value

Indexed keywords

BACTERIAL VACCINE; VIRUS VACCINE;

COST BENEFIT ANALYSIS; DIARRHEA; ECONOMICS; GASTROENTERITIS; HUMAN;

BACTERIAL VACCINES; COST-BENEFIT ANALYSIS; DIARRHEA; GASTROENTERITIS; HUMANS; VIRAL VACCINES;

EID: 84905816359     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29352     Document Type: Review

References (125)

1. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE. Global burden of childhood pneumonia and diarrhoea. Lancet 2013; 381:1405-16; PMID:23582727; http://dx.doi.org/10.1016/S0140-6736(13) 60222-6
2. Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM, Patel MM, Baggs JM, Parashar UD. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine. Pediatrics 2009; 123:744-9; PMID:19254997; http://dx.doi.org/10.1542/peds.2008-1200
3. Yen C, Tate JE, Hyde TB, Cortese MM, Lopman BA, Jiang B, Glass RI, Parashar UD. Rotavirus vaccines: Current status and future considerations. Hum Vaccin Immunother 2014; 10:10; PMID:24755452; http://dx.doi.org/10.4161/hv.28857
4. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, et al.; for the India Rotavirus Vaccine Group. Efficacy of a monovalent humanbovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014; PMID:24629994; http://dx.doi.org/10.1016/S0140-6736(13)62630-6
5. Black S. The role of health economic analyses in vaccine decision making. Vaccine 2013; 31:6046-9; PMID:23968768; http://dx.doi.org/10.1016/j.vaccine. 2013.08.008
6. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209-22; PMID:23680352; http://dx.doi.org/10.1016/S0140-6736(13)60844-2
7. Das JK, Tripathi A, Ali A, Hassan A, Dojosoeandy C, Bhutta ZA. Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Public Health 2013; 13(Suppl 3):S11; PMID:24564510
8. Richard SA, Black RE, Gilman RH, Guerrant RL, Kang G, Lanata CF, Mølbak K, Rasmussen ZA, Sack RB, Valentiner-Branth P, et al.; Childhood Malnutrition and Infection Network. Diarrhea in early childhood: short-term association with weight and long-term association with length. Am J Epidemiol 2013; 178:1129-38; PMID:23966558; http://dx.doi.org/10.1093/aje/kwt094
9. Fischer Walker CL, Lamberti L, Adair L, Guerrant RL, Lescano AG, Martorell R, Pinkerton RC, Black RE. Does childhood diarrhea influence cognition beyond the diarrhea-stunting pathway? PLoS One 2012; 7:e47908; PMID:23118906; http://dx.doi.org/10.1371/journal.pone.0047908
10. Porter CK, Choi D, Cash B, Pimentel M, Murray J, May L, Riddle MS. Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. BMC Gastroenterol 2013; 13:13; PMID:23324408
11. DeBoer MD, Chen D, Burt DR, Ramirez-Zea M, Guerrant RL, Stein AD, Martorell R, Luna MA. Early childhood diarrhea and cardiometabolic risk factors in adulthood: the Institute of Nutrition of Central America and Panama Nutritional Supplementation Longitudinal Study. Ann Epidemiol 2013; 23:314-20; PMID:23608305; http://dx.doi.org/10.1016/j.annepidem.2013.03.012
12. Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr 2013; 31:299-307; PMID:24288942; http://dx.doi.org/10.3329/jhpn.v31i3.16515
13. Deyoung KH, Riddle MS, May L, Porter CK. A case-control study of incident rheumatological conditions following acute gastroenteritis during military deployment. BMJ Open 2013; 3:e003801; PMID:24319273
14. Bärnighausen T, Bloom DE, Cafiero ET, O'Brien JC. Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil. Semin Immunol 2013; 25:104-13; PMID:23886895; http://dx.doi.org/10.1016/ j.smim.2013.04.010
15. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 2007; 25:5945-57; PMID:17629362; http://dx.doi.org/ 10.1016/j.vaccine.2007.04.070
16. Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health 2012; 12:9; PMID:22221895; http://dx.doi.org/10.1186/1471-2458-12-878
17. Rheingans R, Kukla M, Adegbola RA, Saha D, Omore R, Breiman RF, Sow SO, Onwuchekwa U, Nasrin D, Farag TH, et al. Exploring household economic impacts of childhood diarrheal illnesses in 3 African settings. Clin Infect Dis 2012; 55(Suppl 4):S317-26; PMID:23169944
18. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097; PMID:19621072; http://dx.doi.org/10.1371/ journal.pmed.1000097
19. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine 2012; 30:7097-104; PMID:23026689; http://dx.doi.org/10.1016/j.vaccine.2012.09.040
20. Riddle MS, Tribble DR, Cachafiero SP, Putnam SD, Hooper TI. Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth? Vaccine 2008; 26:2490-502; PMID:18417259; http://dx.doi.org/10.1016/j.vaccine.2008.03.008
21. Kim D, Canh G, Poulos C, Thoa TK, Cook J, Hoa NT, Nyamete A, Thuy DT, Deen J, Clemens J, et al. Private demand for cholera vaccines in Hue, Vietnam. Value Health 2008; 11:119-28; PMID:18237366
22. Sardar T, Mukhopadhyay S, Bhowmick AR, Chattopadhyay J. An optimal cost effectiveness study on Zimbabwe cholera seasonal data from 2008-2011. PLoS One 2013; 8:e81231; PMID:24312540; http://dx.doi.org/10.1371/journal.pone.0081231
23. Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis 2012; 6:e1844; PMID:23056660; http://dx.doi.org/10. 1371/journal.pntd.0001844
24. López-Gigosos R, Garcia-Fortea P, Calvo MJ, Reina E, Diez-Diaz R, Plaza E. Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea. BMC Infect Dis 2009; 9:65; PMID:19445712; http://dx.doi.org/10.1186/1471-2334-9-65
25. Lundkvist J, Steffen R, Jönsson B. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. J Travel Med 2009; 16:28-34; PMID:19192125; http://dx.doi.org/10.1111/j.1708-8305. 2008.00270.x
26. Papadimitropoulos V, Vergidis PI, Bliziotis I, Falagas ME. Vaccination against typhoid fever in travellers: a cost-effectiveness approach. Clin Microbiol Infect 2004; 10:681-3; PMID:15301670; http://dx.doi.org/10.1111/j. 1469-0691.2004.00901.x
27. Berry SA, Johns B, Shih C, Berry AA, Walker DG. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010; 202(Suppl):S108-15; PMID:20684689; http://dx.doi.org/10.1086/653578
28. Cook J, Jeuland M, Maskery B, Lauria D, Sur D, Clemens J, Whittington D. Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. J Policy Anal Manage 2009; 28:6-28; PMID:19090047; http://dx.doi.org/10.1002/pam.20401
29. Cook J, Sur D, Clemens J, Whittington D. Evaluating investments in typhoid vaccines in two slums in Kolkata, India. J Health Popul Nutr 2009; 27:711-24; PMID:20099754
30. Jeuland M, Lucas M, Clemens J, Whittington D. A Cost-Benefit Analysis of Cholera Vaccination Programs in Beira, Mozambique. World Bank Econ Rev 2009; 23:235-67; http://dx.doi.org/10.1093/wber/lhp006
31. Lauria DT, Maskery B, Poulos C, Whittington D. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine 2009; 27:1609-21; PMID:19146902; http://dx.doi.org/10.1016/j. vaccine.2008.12.032
32. Sansom SL, Barker L, Corso PS, Brown C, Deuson R. Rotavirus vaccine and intussusception: how much risk will parents in the United States accept to obtain vaccine benefits? Am J Epidemiol 2001; 154:1077-85; PMID:11724726; http://dx.doi.org/10.1093/aje/154.11.1077
33. Connolly MP, Topachevskyi O, Standaert B, Ortega O, Postma M. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics 2012; 30:681-95; PMID:22788259; http://dx.doi.org/10.2165/11597750-000000000-00000
34. Kotsopoulos N, Connolly MP, Postma MJ, Hutubessy RCW. Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine 2013; 31:5430-4; PMID:24055088; http://dx.doi.org/10.1016/j.vaccine. 2013.09.002
35. Centenari C, Gurgel RQ, Bohland AK, Oliveira DM, Faragher B, Cuevas LE. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings? Vaccine 2010; 28:4162-8; PMID:20417608; http://dx.doi.org/10.1016/j.vaccine.2010.04.015
36. Constenla D, Velázquez FR, Rheingans RD, Antil L, Cervantes Y. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Publica 2009; 25:481-90; PMID:19695142; http://dx.doi.org/10.1590/S1020- 49892009000600003
37. Rheingans R, Atherly D, Anderson J. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and costeffectiveness. Vaccine 2012; 30(Suppl 1):A15-23; PMID:22520124; http://dx.doi.org/10.1016/j.vaccine.2012.01.018
38. Tate JE, Rheingans RD, O'Reilly CE, Obonyo B, Burton DC, Tornheim JA, Adazu K, Jaron P, Ochieng B, Kerin T, et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. J Infect Dis 2009; 200(Suppl 1):S76-84; PMID:19817618; http://dx.doi.org/10.1086/605058
39. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine 2013; 31:4902-10; PMID:23871824; http://dx.doi.org/10.1016/j.vaccine.2013.07.014
40. Lin A, Arnold BF, Afreen S, Goto R, Huda TM, Haque R, Raqib R, Unicomb L, Ahmed T, Colford JM Jr., et al. Household environmental conditions are associated with enteropathy and impaired growth in rural Bangladesh. Am J Trop Med Hyg 2013; 89:130-7; PMID:23629931; http://dx.doi.org/10.4269/ajtmh.12-0629
41. Ashraf S, Huque MH, Kenah E, Agboatwalla M, Luby SP. Effect of recent diarrhoeal episodes on risk of pneumonia in children under the age of 5 years in Karachi, Pakistan. Int J Epidemiol 2013; 42:194-200; PMID:23378152; http://dx.doi.org/10.1093/ije/dys233
42. Pattanayak SK, Yang JC, Whittington D, Kumar KCB. Coping with unreliable public water supplies: Averting expenditures by households in Kathmandu, Nepal. Water Resour Res 2005; 2005:41
43. Okeke IN. Cholera vaccine will reduce antibiotic use. Science 2009; 325:674; PMID:19661401; http://dx.doi.org/10.1126/science.325-674b
44. Bhan MK, Glass RI, Ella KM, Bhandari N, Boslego J, Greenberg HB, Mohan K, Curlin G, Rao TS. Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development. Lancet 2014; PMID:24629993; http://dx.doi.org/10.1016/S0140-6736(14)60191-4
45. Abbott C, Tiede B, Armah G, Mahmoud A. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. Vaccine 2012; 30:2582-7; PMID:22321664; http://dx.doi.org/10.1016/j.vaccine. 2012.01.076
46. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009; 200(Suppl 1):S28-38; PMID:19817610; http://dx.doi.org/10.1086/605033
47. Atherly DE, Lewis KDC, Tate J, Parashar UD, Rheingans RD. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine 2012; 30(Suppl 1):A7-14; PMID:22520139; http://dx.doi.org/10. 1016/j.vaccine.2011.12.096
48. Bakir M, Standaert B, Turel O, Bilge ZE, Postma M. Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine 2013; 31:979-86; PMID:23219433; http://dx.doi.org/10.1016/j.vaccine.2012.11.071
49. Chang WC, Yen C, Chi CL, Wu FT, Huang YC, Lin JS, Huang FC, Tate JE, Wu HS, Hsiung CA. Cost-effectiveness of rotavirus vaccination programs in Taiwan. Vaccine 2013; 31:5458-65; PMID:24060569; http://dx.doi.org/10.1016/j.vaccine. 2013.08.103
50. Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J Trop Med Public Health 2010; 41:114-25; PMID:20578490
51. Clark AD, Walker DG, Mosqueira NR, Penny ME, Lanata CF, Fox-Rushby J, Sanderson CFB. Cost-effectiveness of rotavirus vaccination in peru. J Infect Dis 2009; 200(Suppl 1):S114-24; PMID:19817591; http://dx.doi.org/10.1086/605043
52. Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, da Silva LJ. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008; 26:388-96; PMID:19069617
53. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, Anh DD, Agtini M, Bhutta Z, Grp DTES; DOMI Typhoid Economics Study Group. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008; 26:6305-16; PMID:18835415; http://dx.doi.org/10.1016/j.vaccine.2008.09.040
54. Freiesleben de Blasio B, Flem E, Latipov R, Kuatbaeva A, Kristiansen IS. Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan. Emerg Infect Dis 2014; 20:29-37; PMID:24378188; http://dx.doi.org/10.3201/ eid2001.130019
55. De la Hoz F, Alvis N, Narváez J, Cediel N, Gamboa O, Velandia M. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010; 28:3856-64; PMID:20347057; http://dx.doi.org/10.1016/j. vaccine.2010.03.004
56. de Soárez PC, Valentim J, Sartori AMC, Novaes HMD. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008; 23:221-30; PMID:18505602; http://dx.doi.org/10.1590/ S1020-49892008000400001
57. Esposito DH, Tate JE, Kang G, Parashar UD. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis 2011; 52:171-7; PMID:21288839; http://dx.doi.org/10.1093/cid/ciq094
58. Fischer TK, Anh DD, Antil L, Cat NDL, Kilgore PE, Thiem VD, Rheingans R, Tho H, Glass RI, Bresee JS. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192:1720-6; PMID:16235169; http://dx.doi.org/10.1086/497339
59. Flem ET, Latipov R, Nurmatov ZS, Xue YT, Kasymbekova KT, Rheingans RD. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan. J Infect Dis 2009; 200(Suppl 1):S195-202; PMID:19817600; http://dx.doi.org/10.1086/605040
60. Ho AMH, Nelson EAS, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93:52-8; PMID:17855438; http://dx.doi.org/10.1136/adc.2007. 117879
61. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, Bresee JS. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007; 25:373-80; PMID:16930784; http://dx.doi.org/10.1016/j.vaccine. 2006.07.029
62. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D, Grp DCES; DOMI Cholera Economics Study Group. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health 2009; 12:899-908; PMID:19824189; http://dx.doi.org/10.1111/j.1524-4733.2009.00562.x
63. Jeuland M, Whittington D. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs. Vaccine 2009; 27:3109-20; PMID:19428925; http://dx.doi.org/10.1016/j.vaccine.2009.02.104
64. Jit M, Yuzbashyan R, Sahakyan G, Avagyan T, Mosina L. The cost-effectiveness of rotavirus vaccination in Armenia. Vaccine 2011; 29:9104-11; PMID:21945959; http://dx.doi.org/10.1016/j.vaccine.2011.08.127
65. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health 2009; 9:12; PMID:19138392; http://dx.doi.org/10.1186/1471-2458-9-29
66. Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010; 10:24; PMID:20085639; http://dx.doi.org/10.1186/1471-2458-10-253
67. Kim SY, Choi Y, Mason PR, Rusakaniko S, Goldie SJ. Potential impact of reactive vaccination in controlling cholera outbreaks: an exploratory analysis using a Zimbabwean experience. S Afr Med J 2011; 101:659-64; PMID:21920160
68. Kim SY, Sweet S, Chang JH, Goldie SJ. Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden. BMC Infect Dis 2011; 11:17; PMID:21235811; http://dx.doi.org/10.1186/1471-2334-11-174
69. Liu N, Yen C, Fang ZY, Tate JE, Jiang BM, Parashar UD, Zeng G, Duan ZJ. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China. Vaccine 2012; 30:6940-5; PMID:22705174; http://dx.doi.org/10.1016/j.vaccine.2012.05.084
70. Muangchana C, Riewpaiboon A, Jiamsiri S, Thamapornpilas P, Warinsatian P. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand. Vaccine 2012; 30:2839-47; PMID: 22387220; http://dx.doi.org/10.1016/j.vaccine.2012.02.047
71. Ortega O, El-Sayed N, Sanders JW, Abd-Rabou Z, Antil L, Bresee J, Mansour A, Adib I, Nahkla I, Riddle MS. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009; 200(Suppl 1):S92-8; PMID:19817621; http://dx.doi.org/10.1086/605057
72. Patel HD, Roberts ET, Constenla DO. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Vaccine 2013; 31:6072-8; PMID:24176497; http://dx.doi.org/10.1016/j.vaccine.2013.10.022
73. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192(Suppl 1):S133-45; PMID:16088797; http://dx.doi.org/10.1086/ 431513
74. Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. J Health Popul Nutr 2004; 22:311-21; PMID:15609784
75. Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009; 200(Suppl 1):S16-27; PMID:19817595; http://dx.doi.org/10.1086/605026
76. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 2009; 339:b3653; PMID:19783581; http://dx.doi.org/10.1136/bmj.b3653
77. Smith ER, Rowlinson EE, Iniguez V, Etienne KA, Rivera R, Mamani N, Rheingans R, Patzi M, Halkyer P, Leon JS. Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective. Vaccine 2011; 29:6704-11; PMID:21624421; http://dx.doi.org/10.1016/j.vaccine.2011.05.038
78. Stack ML, Ozawa S, Bishai DM, Mirelman A, Tam Y, Niessen L, Walker DG, Levine OS. Estimated Economic Benefits During The 'Decade Of Vaccines' Include Treatment Savings, Gains In Labor Productivity. Health Aff 2011; 30:1021-8; http://dx.doi.org/10.1377/hlthaff.2011.0382
79. Suwantika AA, Tu HAT, Postma MJ. Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account. Vaccine 2013; 31:3300-7; PMID:23707163; http://dx.doi.org/10.1016/j.vaccine.2013.04.055
80. Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011; 29:3329-34; PMID:21241733; http://dx.doi.org/10.1016/j.vaccine. 2010.12.122
81. Tu HAT, Rozenbaum MH, Coyte PC, Li SC, Woerdenbag HJ, Postma MJ. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries. Vaccine 2012; 30:1521-8; PMID:22119590; http://dx.doi.org/10.1016/j.vaccine.2011.11.052
82. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008; 8:103; PMID:18664280; http://dx.doi.org/10.1186/1471-2334-8-103
83. van Hoek AJ, Ngama M, Ismail A, Chuma J, Cheburet S, Mutonga D, Kamau T, Nokes DJ. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines. PLoS One 2012; 7:e47511; PMID:23115650; http://dx.doi.org/10.1371/ journal.pone.0047511
84. Wang XY, Riewpaiboon A, von Seidlein L, Chen XB, Kilgore PE, Ma JC, Qi SX, Zhang ZY, Hao ZY, Chen JC, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009; 49:1202-10; PMID:19739973
85. Whittington D, Jeuland M, Barker K, Yuen Y. Setting Priorities, Targeting Subsidies among Water, Sanitation, and Preventive Health Interventions in Developing Countries. World Dev 2012; 40:1546-68; http://dx.doi.org/10.1016/j. worlddev.2012.03.004
86. Wilopo SA, Kilgore P, Kosen S, Soenarto Y, Aminah S, Cahyono A, Ulfa M, Tholib A. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine 2009; 27(Suppl 5):F67-74; PMID:19931723; http://dx.doi.org/ 10.1016/j.vaccine.2009.09.040
87. Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine 2012; 30:6766-76; PMID:23000223; http://dx.doi.org/10.1016/j.vaccine. 2012.09.025
88. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med Decis Making 2009; 29:33-50; PMID:18948433; http://dx.doi.org/10.1177/0272989X08324955
89. Bruijning-Verhagen P, Mangen MJJ, Felderhof M, Hartwig NG, van Houten M, Winkel L, de Waal WJ, Bonten MJM. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med 2013; 11:17; PMID:23343013; http://dx.doi.org/10.1186/1741- 7015-11-112
90. Chodick G, Waisbourd-Zinman O, Shalev V, Kokia E, Rabinovich M, Ashkenazi S. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. Eur J Public Health 2009; 19:254-9; PMID:19221026; http://dx.doi.org/10.1093/eurpub/ckp005
91. Coyle D, Coyle K, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW, Le Saux N. Cost effectiveness of infant vaccination for rotavirus in Canada. Can J Infect Dis Med Microbiol 2012; 23:71-7; PMID:23730312
92. Dhont P, Trichard M, Largeron N, Rafia R, Bénard S. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium. J Med Econ 2008; 11:431-48; PMID:19450097
93. Diez-Domingo J, Surinach NL, Alcalde NM, Betegon L, Largeron N, Trichard M. Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health 2010; 10:11; PMID:20064250; http://dx.doi.org/10.1186/ 1471-2458-10-469
94. Fisman DN, Chan CH, Lowcock E, Naus M, Lee V. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation. Vaccine 2012; 30:7601-7; PMID:23107595; http://dx.doi.org/10.1016/j.vaccine.2012.10.034
95. Giammanco MD, Coniglio MA, Pignato S, Giammanco G. An economic analysis of rotavirus vaccination in Italy. Vaccine 2009; 27:3904-11; PMID:19446934; http://dx.doi.org/10.1016/j.vaccine.2009.04.002
96. Goossens LMA, Standaert B, Hartwig N, Hövels AM, Al MJ. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26:1118-27; PMID:18215445; http://dx.doi.org/10.1016/j.vaccine. 2007.11.070
97. Huet F, Largeron N, Trichard M, Miadi-Fargier H, Jasso-Mosqueda G. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. Vaccine 2007; 25:6348-58; PMID:17629598; http://dx.doi.org/10.1016/j.vaccine.2007.06.015
98. Imaz I, Rubio B, Cornejo AM, González-Enríquez J. Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain. Prev Med 2014; 61:116-21; PMID:24360847; http://dx.doi.org/10.1016/j. ypmed.2013.12.013
99. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25:3971-9; PMID:17400341; http://dx.doi.org/10.1016/j.vaccine.2007.02.070
100. Jit M, Bilcke J, Mangen MJJ, Salo H, Melliez H, Edmunds WJ, Yazdan Y, Beutels P. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27:6121-8; PMID:19715781; http://dx.doi.org/10.1016/j.vaccine.2009.08.030
101. Kang HY, Kim KH, Kim JH, Kim HM, Kim J, Kim MS, El Khoury AC, Kim DS. Economic evaluation of the national immunization program of rotavirus vaccination for children in Korea. Asia Pac J Public Health 2013; 25:145-58; PMID:22234827; http://dx.doi.org/10.1177/1010539511416806
102. Lorgelly PK, Joshi D, Iturriza Gómara M, Gray J, Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008; 136:44-55; PMID:17335631; http://dx.doi.org/10.1017/S0950268807008151
103. Mangen MJJ, van Duynhoven YT, Vennema H, van Pelt W, Havelaar AH, de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010; 28:2624-35; PMID:20109593; http://dx.doi.org/10.1016/j.vaccine.2010.01.014
104. Martin A, Batty A, Roberts JA, Standaert B. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009; 27:4520-8; PMID:19446594; http://dx.doi.org/10.1016/j.vaccine.2009.05.006
105. Melliez H, Levybruhl D, Boelle PY, Dervaux B, Baron S, Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26:706-15; PMID:18166250; http://dx.doi.org/10.1016/j. vaccine.2007.11.064
106. Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value Health 2009; 12:888-98; PMID:19490550; http://dx.doi.org/10. 1111/j.1524-4733.2009.00534.x
107. Newall AT, Beutels P, Macartney K, Wood J, MacIntyre CR. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25:8851-60; PMID:18022735; http://dx.doi.org/10.1016/j.vaccine.2007.10.009
108. Panatto D, Amicizia D, Ansaldi F, Marocco A, Marchetti F, Bamfi F, Giacchino R, Tacchella A, Del Buono S, Gasparini R. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine 2009; 27:3450-3; PMID:19200850; http://dx.doi.org/10. 1016/j.vaccine.2009.01.054
109. Pérez-Rubio A, Luquero FJ, Eiros Bouza JM, Castrodeza Sanz JJ, Bachiller Luque MR, de Lejarazu RO, Sánchez Porto A. Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain. Infez Med 2011; 19:166-75; PMID:22037437
110. Rozenbaum MH, Mangen MJJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ. Consensus Grp Dutch R. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011; 11:12; PMID:21210992; http://dx.doi.org/10.1186/1471-2458-11-462
111. Sato T, Nakagomi T, Nakagomi O. Cost-effectiveness analysis of a universal rotavirus immunization program in Japan. Jpn J Infect Dis 2011; 64:277-83; PMID:21788701
112. Shim E, Galvani AP. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27:4025-30; PMID:19389452; http://dx.doi.org/10.1016/j.vaccine.2009.04.030
113. Standaert B, Parez N, Tehard B, Colin X, Detournay B. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008; 6:199-216; PMID:19382820; http://dx.doi.org/10.1007/ BF03256134
114. Standaert B, Gomez JA, Raes M, Debrus S, Velázquez FR, Postma MJ. Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. PLoS One 2013; 8:e53864; PMID:23349754; http://dx.doi.org/10.1371/journal.pone.0053864
115. Syriopoulou V, Kafetzis D, Theodoridou M, Syrogiannopoulos GA, Mantagos S, Trimis G, Mavrikou M, Konstantopoulos A. Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece. Acta paediatrica (Oslo, Norway: 1992) 2011; 100:732-9.
116. Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, Barry M. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011; 29:7463-73; PMID:21821085; http://dx.doi.org/10.1016/j.vaccine.2011.07.056
117. Tu HAT, Rozenbaum MH, de Boer PT, Noort AC, Postma MJ. An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model". BMC Infect Dis 2013; 13:5; PMID:23289357; http://dx.doi.org/10.1186/1471-2334-13-54
118. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125:e208-13; PMID:20100757; http://dx.doi.org/10.1542/ peds.2009-1246
119. Weycker D, Sofrygin O, Kemner JE, Pelton SI, Oster G. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. Vaccine 2009; 27:4930-7; PMID:19555715; http://dx.doi.org/10.1016/j. vaccine.2009.06.025
120. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119:684-97; PMID:17403839; http://dx.doi.org/10.1542/ peds.2006-2876
121. Wu CL, Yang YC, Huang LM, Chen KT. Cost-effectiveness of childhood rotavirus vaccination in Taiwan. Vaccine 2009; 27:1492-9; PMID:19186200; http://dx.doi.org/10.1016/j.vaccine.2009.01.023
122. Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy TV, Cortese M, Rodewald L. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics 2014; 133:577-85; PMID:24590750; http://dx.doi.org/10.1542/peds.2013-0698
123. Zlamy M, Kofler S, Orth D, Wurzner R, Heinz-Erian P, Streng A, Prelog M. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis 2013; 13:10; PMID:23298156; http://dx.doi.org/10.1186/1471-2334-13-112
124. Zomer TP, van Duynhoven YT, Mangen MJJ, van der Maas NAT, Vennema H, Boot H, de Melker HE. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008; 26:3757-64; PMID:18514975; http://dx.doi.org/10.1016/j.vaccine.2008.04.039
125. Jit M, Mangen MJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, Edmunds WJ, Beutels P. An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe". Vaccine 2010; 28:7457-9; PMID:20846529